Pranlukast D4
| Product Name | Pranlukast D4 |
|---|---|
| Alternate Names | Pranlukast Stable Isotopes, Stable Isotopes of Pranlukast |
| CAT No. | CS-O-02838 |
| CAS No. | 103177-37-3(Unlabeled) |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 485.53 g/mol |
| Mol. For. | C₂₇H₁₉D₄N₅O₄ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Pranlukast |
| Purity | 97.55 |
| Therapeutic | Anti-Asthma / COPD |
| Smileys | O=C(C1=C([2H])C([2H])=C(OCCCCC2=CC=CC=C2)C([2H])=C1[2H])NC3=C(OC(C4=NN=NN4)=CC5=O)C5=CC=C3 |
| Canonical Smiles | C1=CC=C(C=C1)CCCCOC2=CC=C(C=C2)C(=O)NC3=CC=CC4=C3OC(=CC4=O)C5=NNN=N5 |
| InchIKey | NBQKINXMPLXUET-UHFFFAOYSA-N |
| Inchl | InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32) |
| IUPAC | N-[4-oxo-2-(2H-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Pranlukast D4 is a deuterated analog of pranlukast, a selective antagonist of leukotriene receptor CysLT1. Pranlukast D4 is utilized in clinical research studies involving the pharmacokinetics, pharmacodynamics, and metabolism of pranlukast. The deuterium substitution of the compound enables for improved stability and longevity in the bloodstream, allowing for more accurate measurements and analysis of the compound's effects.
Pranlukast D4 binds to leukotriene receptors, interfering with the action of leukotrienes, which are involved in inflammatory responses. By blocking the CysLT1 receptor, pranlukast D4 reduces airway inflammation and constriction in patients with asthma and allergic rhinitis. The compound has been studied in clinical trials and has shown to be effective in reducing symptoms and improving lung function in patients with asthma.
Pranlukast D4 is administered orally in tablet form and is rapidly absorbed into the bloodstream. The compound is metabolized in the liver through the cytochrome P450 system and has a half-life of approximately 4-6 hours. The majority of the compound is excreted in the urine.
In conclusion, Pranlukast D4 is a useful tool for research purposes, providing insight into the pharmacokinetics and pharmacodynamics of pranlukast. It has shown to be an effective treatment for asthma and allergic rhinitis, improving lung function and reducing inflammation.
Get an Instant Quote
Related Compounds
Pranlukast-d5 |